Stereotactic radiotherapy outcomes for intraventricular brain tumours in 11 dogs

• Published in: Veterinary & comparative oncology Vol. 21; no. 4; pp. 665 - 672
• Main Authors: Hansen, Katherine Sarah, Li, Chai Fei, Théon, Alain Pierre, Kent, Michael Sean
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2023
• Subjects: canine; choroid plexus carcinoma; choroid plexus papilloma; ependymoma; SRS; ventricular mass
• DOI: 10.1111/vco.12929
• ISSN: 1476-5810

Published radiotherapy data for canine intraventricular tumours are limited. In this retrospective, longitudinal study (9/2011–2018), 11 dogs with intraventricular masses were treated with stereotactic radiotherapy (SRT). Pathologic diagnosis was available from surgery or necropsy in 6/11 cases, revealing choroid plexus papilloma (3) or carcinoma (2), and ependymoma (1). The remainder were magnetic resonance imaging (MRI)‐diagnosed as suspected choroid tumours or ependymomas. Tumours were located in the third or lateral ventricle (8), fourth ventricle (2), and cerebellopontine angle (1). Surgery was performed in three dogs prior to radiotherapy, and all showed gross residual/recurrent disease at treatment. Dogs received 8 Gray × 3 fractions (7), or 15 Gray × 1 fraction (4). Ten dogs were deceased at analysis, and one was living. The estimated median overall survival time (OS) from first SRT treatment was 16.9 months (515 days, 95% CI 33–1593 days). The survival time for two pathology‐diagnosed carcinoma dogs were 24 and 133 days, respectively, and survival time for dogs with moderate to marked ventriculomegaly (4/11) ranged from 24 to 113 days. A total of 10/11 showed clinical improvement per owner or clinician, but two had short‐lived benefits and were euthanized within 6 weeks of SRT. Limited conclusions on radiation‐specific complications are possible due to the small dataset and limited follow‐up imaging. This study provides preliminary evidence that radiotherapy outcomes are variable with intraventricular tumours, and some long‐term survivors are noted.